All Press Releases
PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET
Malmö, 10 February 2026 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A. CEO Gustav H. Gram will have an online interview and Q&A at 14:00 CET on 10 February 2026, in connection with the publication of the company's H2 / Year-end report. The event…
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January – December 2025.
Malmö, 10 February 2026 The report can be found on the Company´s website: https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025) Operating income amounted to TSEK 276 (107) The operating result (EBIT) totaled to TSEK -3 802 (-4 030) The result for the period totaled to TSEK -12 761 (-7 155) Earnings per share, basic and…
PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA
Malmö, 09 February 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that it has initiated preparations for a clinical trial application for a proof-of-concept study in the rare disease erythromelalgia. The ambition is to develop PILA PHARMA's oral TRPV1 inhibitor as…